PharmAthene Inc (NYSEMKT:PIP) said Monday that the Department of Health and Human Services has decided to scale back and partially terminate its SparVax anthrax vaccine contract. PharmAthene, Inc. (NYSEMKT:PIP) shares after opening at $1.52 moved to $1.52 on last trade day and at the end of the day closed at $1.44. Company price to sales ratio in past twelve months was calculated as 4.31 and price to cash ratio as 7.35. PharmAthene, Inc. (NYSEMKT:PIP) showed a negative weekly performance of -16.76%.
VIVUS, Inc. (NASDAQ:VVUS) presented an overview of the company at the 13th Annual Needham Healthcare Conference on April 8, 2014, 3:40pm EDT at The Westin Grand Central Hotel, New York. VIVUS, Inc. (NASDAQ:VVUS) shares fell -1.80% in last trading session and ended the day on $4.91. VVUS return on equity ratio is recorded as -104.50% and its return on assets is -46.80%. VIVUS, Inc. (NASDAQ:VVUS) yearly performance is -57.38%.
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced that the United States Patent and Trademark Office has granted Patent No. 8,685,460 for the treatment of heat stroke with Eagle’s dantrolene sodium for injectable suspension (“dantrolene”). The patent issued expires in 2023. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) shares moved down -5.92% in last trading session and was closed at $11.92 while trading in range of $11.70 – $12.71 – Eagle Pharmaceuticals Inc (NASDAQ:EGRX) year to date (YTD) performance is -10.11%.
TearLab Corporation (NASDAQ:TEAR) through its wholly-owned subsidiary, OccuLogix LLC, (the “Sub”) entered into an asset purchase agreement (the “Purchase Agreement”) with AOAExcel, Inc. (“AOA”) and, in connection with the Purchase Agreement, consummated the purchase from AOA of assets specifically related to AOA’s cloud-based, single sign-on portal technology used to secure connectivity between doctors, patients, institutions and payers (the “OcuHub Business”) (the “Transaction”). TearLab Corp (NASDAQ:TEAR) weekly performance is -7.34%. On last trading day company shares ended up $5.93. TearLab Corp (NASDAQ:TEAR) distance from 50-day simple moving average (SMA50) is -15.36%. Analysts mean target price for the company is $12.40.